Citius Oncology, Inc

Citius Oncology is headquartered in Cranford, New Jersey and is focused on commercializing LYMPHIR independently in the United States. The company’s launch strategy is concentrated on key U.S. geographies and major cancer centers, reflecting the specialist nature of CTCL treatment. Outside the U.S., the company intends to partner rather than build its own commercial infrastructure, which limits direct international operating exposure. The underlying license rights cover most markets outside Japan and certain parts of Asia, but the company has not yet built a broad ex-U.S. commercial footprint. As a result, near-term business activity is overwhelmingly U.S.-centric, with international value expected to come through partnering and royalties rather than direct sales.

The company faces substantial going-concern and financing risk because it has no revenue, limited cash, and ongoing obligations for milestones and supply purchases. Commercial execution risk is high because LYMPHIR is a newly launched niche therapy and adoption depends on specialist prescribers, reimbursement, and real-world physician confidence. Manufacturing and supply-chain dependence is another major risk because the company relies on third-party manufacturers and contract packaging vendors, and any disruption could delay supply or increase costs. Governance and control risk is also material because Citius Pharma owns a controlling stake and can influence board composition and corporate actions. More broadly, the company is exposed to typical biopharma risks such as regulatory compliance, competition from larger oncology companies, intellectual property disputes, and uncertainty around future clinical or commercial outcomes.